TREMFYA 200 MG/2 ML PEN

What it is

TREMFYA 200 MG/2 ML PEN is how the CMS NADAC file names this product. The FDA NDC Directory lists it as guselkumab, under the trade name “TREMFYA”.

FDA gives its dosage form as injection and its route as subcutaneous.

The labeler, the company named on the label, is Janssen Biotech, Inc.

FDA’s Established Pharmacologic Class for it is Interleukin-23 Antagonist.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes); the FDA directory lists 1 of them.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $14,643.31 for 2 mL (2 × $7,321.65571 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

What NADAC measures · NADAC explanation codes

All 2 NDCs

• 57894-0651-01 · not listed as a package in the FDA directory · $7,321.65571 per ML · eff. 2026-09-23 filed
• 57894-0651-02 · Janssen Biotech, Inc. · $7,321.65571 per ML · eff. 2026-09-23 filed

Other strengths, forms and brands

3 other products in the NADAC file share the FDA nonproprietary name guselkumab with TREMFYA 200 MG/2 ML PEN.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

OpenBill calculation · october-2026-medicare-part-b-payment-limit-files-final.zip + october-2026-ndc-hcpcs-crosswalk-final.zip · Part B limit 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18) · Part B crosswalk 2026-10-01 to 2026-12-31 (file of 2026-09-17, retrieved 2026-10-18)

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $7,321.65571 per ML filed.

Of the 10 other products in FDA’s Interleukin-23 Antagonist class priced per ML, 7 have a higher middle NADAC price and 3 a lower one. The one in the middle is TREMFYA 100 MG/ML SYRINGE, at $14,728.90533 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

Medicare Part B’s payment limit for HCPCS J1628, for 2026-10-01 to 2026-12-31, comes to $13,399.60 for 2 mL, or $6,699.80 per ML once converted to NADAC’s unit for this product.

Medicare Part B pays for a drug like this only in specific settings, such as a drug given in a clinic or doctor’s office or used with certain medical equipment; most prescriptions filled at a pharmacy are paid by Part D.

The patient’s share under Part B (coinsurance, 20% of the limit, before deductibles and other coverage) is $13.3996 per 1 MG.

1 of the product’s 2 NDCs have this Medicare figure; the other 1 do not, and the interactive card says why for each.

Medicare's price is not your price.

What the Part B payment limit is · Converting it to the NADAC unit · How the spread is worked out

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 2 mL? Is it lower than what I would pay through my insurance?
• How much is in the package I am getting? This page uses 2 mL; your package may hold a different amount.
• If you have Medicare Part B: is this drug covered for me in this setting, and what is my share?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.